Intarcia boosts private cash with $1bn-plus Servier deal

For Intarcia Therapeutics, which wanted to retain 100% of the domestic rights to its once-yearly diabetes drug, Servier turned out to be the best possible partner to commercialize ITCA 650 in foreign markets given the French pharmaceutical firm's long-standing aversion to the US market.